# US 2024/0307524 A1 · Coronavirus vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0307524 A1
- Document ID: US20240307524A1
- Status: Published application
- Kind: A1
- Application number: 18/576,969
- Filed: 2022-07-07
- Published: 2024-09-19
- Earliest claimed: 2021-07-07
- Assignees: Luxembourg Institute of Health (LIH)
- Applicants: Luxembourg Institute of Health (LIH)
- Inventors: Xavier Dervillez; Catherine Léonard; Markus Wolfgang Ollert
- Web page: https://patentgrep.com/patent/US20240307524A1

## CPC

- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C07K 2319/21: containing a His-tag
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/735: containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
- C12N 2770/00022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/00034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides multimeric protein complex comprising three polypeptides each comprising N- to C-terminally: (i) a receptor-binding domain (RBD) of an S1 subunit of an S protein of a coronavirus, (ii) optionally a S2 subunit of an S protein of a coronavirus; and (iii) a multimerization domain comprising a collagen-like region (CLR) of ficolin-2, wherein the multimerization domain enables the assembly of the polypeptides into a multimeric protein complex. The present invention further provides polynucleotides encoding the polypeptides of the multimeric protein complex, expression vectors, pharmaceutical compositions and uses of the multimeric protein complexes, such as a vaccine.

## Claims

### Claim 1

A multimeric protein complex comprising three polypeptides each comprising N- to C-terminally:
(i) a receptor-binding domain (RBD) of an S1 subunit of a Spike (S) protein of a coronavirus,
(ii) optionally a S2 subunit of an S protein of a coronavirus; and
(iii) a multimerization domain comprising a collagen-like region (CLR) of ficolin-2, wherein the multimerization domain enables the assembly of the polypeptides into a trimeric protein complex,

### Claim 2 (depends on 1)

The multimeric protein complex according to claim 1, wherein the multimerization domain comprises at most 75 amino acids.

### Claim 3 (depends on 1)

The multimeric protein complex according to claim 1, wherein the multimerization domain comprises from 1 to 3 cysteines.

### Claim 4 (depends on 1)

The multimeric protein complex according to claim 1, wherein the multimerization domain consists of (i) the CLR of ficolin-2; or (ii) the CLR of ficolin-2 and immediately C-terminally of the CLR of ficolin-2 a peptide consisting of three amino acids of which one is a cysteine, optionally wherein the peptide corresponds to the first three amino acids of the fibrinogen-like region (FLR) of ficolin-2.

### Claim 5 (depends on 1)

The multimeric protein complex according to claim 1, wherein the polypeptides each comprise a linker peptide C-terminally of the S2 subunit of the S protein of the coronavirus and N-terminally of the multimerization domain.

### Claim 6 (depends on 1)

The multimeric protein complex according to claim 1, wherein at least one of the polypeptides comprises at its C-terminal end a tag, optionally wherein the tag comprises N-terminally a proteolytic cleavage site.

### Claim 7 (depends on 1)

The multimeric protein complex according to claim 1, wherein the polypeptides each comprise the complete S1 subunit and the S2 subunit of the S protein of the coronavirus.

### Claim 8 (depends on 7)

The multimeric protein complex according to claim 7, wherein the S1/S2 cleavage site is mutated, thereby preventing proteolytic processing of S protein in the S1 and S2 subunits.

### Claim 9 (depends on 1)

A polynucleotide encoding a polypeptide of the multimeric protein complex according to claim 1.

### Claim 10 (depends on 9)

The polynucleotide according to claim 9, wherein the polynucleotide does not comprise a sequence encoding the signal peptide or part of the signal peptide of the coronavirus S protein.

### Claim 11 (depends on 9)

An expression vector comprising the polynucleotide according to claim 9.

### Claim 12

A method for preparing a trimeric protein complex, comprising
(a) introducing a polynucleotide encoding a polypeptide comprising N- to C-terminally:
(i) a receptor-binding domain (RBD) of an S1 subunit of a Spike (S) protein of a coronavirus,
(ii) optionally a S2 subunit of an S protein of a coronavirus; and
(iii) a multimerization domain comprising a collagen-like region (CLR) of ficolin-2, wherein the multimerization domain enables the assembly of the polypeptides into a trimeric protein complex, into a host cell,
(b) allowing the host cell to express and secrete the polypeptides, resulting in the self-multimerization of the polypeptides into trimeric protein complexes; and
(c) separating the trimeric protein complexes from the supernatants.

### Claim 13 (depends on 12)

A trimeric protein complex obtainable by or obtained by the method according to claim 12.

### Claim 14

A composition comprising a combination of protein complexes, the protein complexes comprising three polypeptides, each comprising N- to C-terminally:
(i) a RBD of an S1 subunit of an S protein of a coronavirus,
(ii) optionally a S2 subunit of an S protein of a coronavirus; and
(iii) a multimerization domain comprising a CLR of ficolin-2, wherein the polypeptides have not assembled, or the polypeptides have assembled into trimeric protein complexes by way of said multimerization domain.

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the multimeric protein complex according to claim 1, and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 1)

A vaccine comprising a multimeric protein complex according to claim 1.

### Claim 17

(canceled)

### Claim 18 (depends on 1)

A method of preventing a coronavirus infection in a subject, the method comprising administering to said subject, the multimeric protein complex according to claim 1 so as to prevent a coronavirus infection.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said coronavirus infection is a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) infection.
